INTRODUCTION
The bacillus of Calmette and Guirin (BCG) is a particularly attractive vector for the development of recombinant vaccines (Bloom, 1989) . It has already been used to immunize more than 2.5 billion people with a very low incidence of serious complications and it can be given at or any time after birth. BCG itself is a potent adjuvant: a single inoculum can elicit long-term immunity (Bloom, 1989) .
A growing array of integrative and extrachromosomal expression vectors has been developed over recent years, enabling cloning and expression of foreign genes in BCG (Snapper e t al., 1988; Ranes et al., 1990; Matsuo et al., 1990) . Various expression cassettes have been described for efficient expression of HIV1 Gag and Env structural proteins (Aldovini & Young, 1991 ; Stover e t al., 1991) , and the regulatory protein Nef (Winter et al., 1991) , tetanus toxin and P-galactosidase (Stover e t al., 1991 ;  . 
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BCG, bacillus of Calmette and Guerin; CL, cutaneous leishmaniasis; i.v., intravenous(1y); s.c., subcutaneous(1y). Murray et al., 1992) in BCG. Several recombinant BCG strains induce specific cellular and humoral immune responses in mice (Aldovini & Young, 1991 ; Stover e t al., 1991 ; Winter et al., 1991 ; Murray e t al., 1992) . Protective immunity against Lyme disease elicited by recombinant BCG against challenge with Borrelia bwgdorferi has also been reported (Stover e t al., 1993) . Leishmania are obligate intracellular protozoan parasites of macrophages. They cause leishmaniasis, a major infectious disease of considerable public health and economic importance (WHO, 1984) . Leishmaniasis includes a broad spectrum of diseases, ranging from simple cutaneous to visceral leishmaniasis (Chang & Bray, 1985) , according to the parasite species and to the host's susceptibility.
With the aim of developing a recombinant vaccine against cutaneous leishmaniasis, we cloned and expressed the @63 gene of Leishmania major (the causative agent) in BCG. Vaccination against cutaneous leishmaniasis is feasible in principle, since individuals who develop the disease acquire long-term immunity against reinfection. Deliberate infection with the virulent cutaneous leish- 
mania1 parasite has been the basis for vaccination programmes in Israel and in countries of the former USSR (Greenblatt, 1980) . However, complications associated with such immunization indicated the need for a killed, attenuated or subunit vaccine for CL. Killed Leisbmania organisms and soluble extracts of promastigotes have been successfully used for immunizing animals (Howard etal., 1984; Liew etal., 1984; Mitchell & Handman, 1983; Scott et al., 1987) and humans (Adler & Gunders, 1964; Lainson & Shaw, 1977; Mayrink etal., 1985) . In addition, administration to mice of several purified leishmanial antigens including lipophosphoglycan (Handman & Mitchell, 1985) , surface glycoproteins, Gp63 (Russell & Alexander, 1988) and Gp46/M2 (Champsi & McMahonPratt, 1 988), confers significant protection against leishmaniasis. Effective immunization with these subunit vaccines requires continuous boosters in the presence of an adjuvant. However the same antigen can induce protection against or exacerbation of the disease depending on the route of vaccination (Liew e t al., 1985a, Live recombinant vaccines, expressing leishmanial antigens, have been recently investigated as delivery systems for inducing appropriate and long-term immunological responses leading to protection against challenge with Leisbmania parasites. Different inbred mice strains can be classified as resistant or susceptible to leishmaniasis (reviewed by Blackwell, 1989; Blackwell e t al., 1991) . Resistant CBA mice orally immunized with the AroAvaccine strain of Salmonella t_ypbimtlrizim transformed with the full-length L. majorgp63 gene preferentially developed a T h l response that led to protective immunity against infection with Leisbmania mexicana (Yang e t al., 1990) . Susceptible BALB/c mice immunized with recombinant vaccinia virus expressing GP46/M2 were significantly protected against a challenge with Leisbmania amaponensis (McMahon-Pratt et al., 1993) . A recent report (Connell et al., 1993) has shown that BCG expressing Gp63 as a fusion protein with the BCG bsp60 gene product engendered a protective response against a challenge with L. mexicana promastigotes and amastigotes after immunization of CBA and BALB/c mice. This recombinant BCG strain protected resistant CBA mice but not susceptible BALB/c mice against a challenge with L. major, although lesion development within this group was less severe than in untreated and BCG control groups (Connell e t al., 1993) . We analysed the expression of the ~6 3 gene of L. major under the control of two different mycobacterial expression systems. The ability of the recombinant BCGgp63 vaccines to induce protective immunity against a challenge with L. major was evaluated after vaccination of susceptible (BALB/c) or resistant (C57BL/6) mouse strains. One of the expression systems led to significant protection against a challenge with L. major in immunized BALB/c mice. b).
METHODS
Bacterial strains, plasmids, parasites and culture conditions. The bacterial strains, plasmids and parasites used in this study are listed in Table 1 . Eschericbia coli strains were grown in Lbroth supplemented with appropriate antibiotics and were transformed as described by Sambrook et al. (1989) . Mycobacterial strains were transformed by electroporation as described previously (Ranes et al., 1990) . Recombinant BCG clones were first cultivated on Lowenstein-Jensen medium containing 10 pg kanamycin ml-', then transferred onto Sauton medium for classical vaccine preparation or grown as a dispersed culture (Gheorghiu e t al., 1988) . L. major strain TN435 was cultured in RPMI 1640 supplemented with 10 % inactivated foetal calf serum (Hyclone Laboratories) (Jaffe et al., 1984) . L. major amastigotes were obtained by passaging strain PSA. 18. SBZ, isolated from the rodent Psammomys obestls from the region of Sidi Bou Zid (Tunisia), and passaged in vivo five times in BALB/c mice.
Construction of expression vectors. The Gp63 protein precursor of L. major is encoded by an ORF of 1.8 kb, of which 1-5 kb encodes the mature form of Gp63 (Button & McMaster, 1988) . The DNA fragment coding for the mature protein was synthesized in vitro by PCR amplification from genomic DNA of L. major strain TN435 (kindly provided by R. Ben Ismail, Institut Pasteur de Tunis : Ben Ismail e t al., 1986). Translational initiation and termination codons, and restriction sites for the subsequent cloning, were added. The sequences of the 5' and 3' primers are 5'-GCGGGATCCTTATGCATGTGCGCGACG-TGAACTGGGGC-3' (the BamHI and Nszl sites are underlined) and 5'-CCGAATTCAAGCTTCTACGCCGTGTTGC-CGCCGTCCTT-3' (the Hind111 site is underlined); an ATG start codon and a stop codon were included (in bold).
The gp63 gene was then cloned in plasmids pAM311 and pIPJ42*. Plasmid pAM311 is a pUC18 derivative containing a 1.6 kb fragment from Mycobacteritlm paratuberculosis harbouring the PAN promoter and ORF2 (Murray et al., 1992) . Plasmid pIPJ42* is a pUC18 vector harbouring at the BamHI site the /?-lactamase gene blaF with the regulatory region of blaF*, which overproduces /I-lactamase (Timm et al., 1994a) . pIPJ46 is a pSLl180 derivative harbouring the origin of replication, oriM, of the M.forttlitum plasmid pAL5000 (Ranes et al., 1990) and the kanamycin-resistance gene, aph, from Tn903 (Kanamycin Resistance Gen-Block, Pharmacia). pIPJ46 was used as a source of the oriMaph cassette for both the E. coli/mycobacteria shuttle plasmids, which were named PIPS1 1 (pAM311 derivative) and pIPS42 (PIP J42* derivative). These plasmids were introduced into M. smegmatis and BCG by electroporation as previously described (Winter e t al., 1991) .
SDSPAGE and Western blotting. Total protein extracts of M.
bovis BCG strains were prepared as described previously (Winter et al., 1991) . Proteins were separated on 0.1 ' / o SDS-10 YO (w/v) polyacrylamide gels according to Laemmli (1 970). After electroblotting, the membranes were incubated with a monoclonal antibody directed against Gp63 produced in E. coli (kindly provided by W. R. MacMaster, University of British Columbia, Vancouver, Canada: Button e t al., 1991). The membranes were washed and incubated with horseradish-peroxidase-conjugated sheep anti-mouse second antibody and developed with the ECL chemiluminescent substrate according to the manufacturer's instructions (Amersham).
Evaluation of protection against infection with L. major.
Four groups of 8-10 BALB/c or C57BL/6 mice were immunized twice at a one-month interval with lo6 c.f.u. given intravenously (i.v.) or 10' c.f.u. given subcutaneously (s.c.) of Protection studies using gp63 recombinant BCG and IPS11, or no vaccine (naive mice). One month after the booster injection, mice were challenged in one hind footpad with 2 x 10, amastigotes isolated from the footpad of an infected mouse, as follows. The foot was ground with a cell dissociation sieve-tissue grinder kit (Sigma). Amastigotes were counted and resuspended in PBS at a concentration of 4 x lo7 ml-'.
The footpad swelling was estimated by measurement of the foot circumference and subtracting the foot circumference on the day of challenge. At the end of the experiment (120 d after challenge) mice were killed and parasites were recovered from the footpad and counted as described above. (100 U ml-'), streptomycin (50 pg ml-'), and 50 pM 2-mercaptoethanol. Promastigotes from L. major strain TN435 were sonicated and centrifuged at 47 000 g and the supernatant containing soluble leishmanial antigens (Sacks e t a/., 1987), was used as stimulating antigen at the final concentration of 20 pg ml-'. Cultures were incubated at 37 "C with 5 % CO,, and on day 5, cells were pulsed with 0.5 pCi (18.5 kBq) Statistical tests. Data were analysed for statistical significance by using the Mann-Whitney U test, which is the nonparametric version of the two-group unpaired t-test. Data were considered significant at P < 0.05.
RESULTS

Cloning and expression of gp63 in BCG
Two different systems were used to drive the expression ofgp63 in BCG. The first system allows the production of heterologous proteins in mycobacteria as fusions with the N-terminus of the protein encoded by ORF2, an open reading frame of 382 codons which belongs to the insertion sequence IS700 isolated from M. parattlberctllosis. bacteria shuttle plasmids were named respectively PIPS1 1 and pIPS42. These plasmids were introduced into M.
smegmatis and BCG by electroporation as previously described (Winter e t al., 1991) . Expression of the fusion is driven by P A N , a promoter located upstream of ORF2 (Murray e t al., 1992) . Previous studies have shown that analogous fusions of the lac2 gene to the ORF2 sequence result in the production of fusion proteins with p-galactosidase activity in BCG (Murray e t al., 1992) . This recombinant BCG elicited T cell proliferative responses and anti-p-galactosidase antibody production in immunized mice.
The second expression system was recently developed for the production and export of heterologous proteins in mycobacteria (Timm e t al., 1994a) . This system relies on the production of antigenic fragments as fusions with the N-terminal region of P-lactamase (BlaF). Expression is driven by a mutant of the p-lactamase gene promoter (pblaF*) isolated from an M. forttlittlm strain overproducing p-lactamase.
The @63 gene was synthesized in vitro by PCR amplification from genomic DNA of L. major strain TN435 and then cloned into plasmids harbouring the expression cassettes described above. The resulting E. coli/ mycoThe production of the fused Gp63 proteins in BCG was assessed by Western blot analysis of total protein extracts using an anti-Gp63 monoclonal antibody (Fig. 1) . The antibody recognized two major products in recombinant BCG strains : 73 kDa and 63 kDa polypeptides, corresponding to the fusion products between Gp63 and, respectively, the N-terminal part of the polypeptide encoded by ORF2 and p-lactamase. The amount of the p-lactamase-Gp63 hybrid was consistently higher than that of the hybrid of Gp63 with the polypeptide encoded by ORF2 (Fig. 1 and data not  shown) . This is in accordance with recent studies showing that lac2 expression in BCG from pblaF* resulted in a pgalactosidase activity in transformed BCG which was 6 times higher than that from PAN (Timm et al., 1994b) . The p-lactamase-Gp63 fusion protein was found only in the total extract of the recombinant BCG cells and not in the culture medium (data not shown). This is consistent with previous studies showing that the signal sequence is essential but not sufficient for protein export (Moreno e t al., 1980) . 
Protection against f. major infection
Four groups of 8-10 BALB/c or C57BL/6 mice were immunized with two injections, at a one-month interval, of BCG or recombinant BCG by two different inoculation routes, i.v. or S.C. A control group of each mouse strain was not immunized. One month after the booster injection the mice were challenged with 2~ lo6 L.major amastigotes. The development of cutaneous lesions was followed for 11 weeks after infection by measuring footpad swelling (Fig. 2) .
The L. major strain TN435 caused a progressive disease in BALB/c mice, but a self-resolving disease in C57BL/6 mice ( Fig. 2) . The ulcerative lesions induced in BALB/c mice by L. major strain TN435 were smaller than those caused by other strains described in the literature (8-15 mm). Despite the small size of the lesions, visceralization and severe evolution of the disease was observed, leading to the death of the animals.
BALB/c mice inoculated with BCG producing the /?-lactamase-Gp63 fusion protein (IPS42) had significantly ( P < 0.05) smaller lesions than controls.
IPS42 recombinant BCG administered by either route restricted lesion development. However, i.v. administration was associated with a more rapid regression of the lesion: its diameter regressed significantly ( P < 0.05) from day 22 ( fig. 2) . Mouse groups immunized, by the S.C. or the i.v. route, with the non-recombinant BCG (1173P2) vaccine or with the recombinant BCG producing the ORF2-Gp63 fusion (IPS1 1) developed ulcerous lesions similar in size to those in the non-immunized control group.
C57BL/6 mice which did not receive BCG developed only a footpad swelling that regressed 6 weeks after challenge with L. major amastigotes, as has been reported for other mouse strains resistant to infection with L. major. The C57BL/6 mice, immunized S.C. or i.v. with BCG or with either recombinant BCG-gp63, developed footpad swelling similar to that in the control group. Lesion development in C57BL/6 mice, naturally resistant to L. major infection, was less pronounced only after i.v. immunization with BCG. This is consistent with previous reports describing a protective effect of BCG against L. major infection in mice (Fortier e t al., 1987 ; Connell e t al., 1993) . In contrast to the control group, the footpad swelling of the immunized C57BL/6 mice did not regress completely 8 weeks after challenge. These lesions appeared different from those induced in susceptible BALB/c mice: they were not ulcerated and were free of parasite on day 51 and at the end of the study. A histological examination of the foodpad swelling, performed in two mice of these groups, showed a faint interstitial oedema and a subcutaneous infiltrate of lymphocytes with few histiocytic cells. N o Leishman bodies were detected.
Evaluation of parasite load and cellular immune responses
The best protection against L. major infection was thus obtained in BALB/c mice with recombinant BCG expressing Gp63 as a fusion protein with the N-terminal region of /?-lactamase (IPS42). Since the subcutaneous route of immunization appeared promising, we evaluated the cellular immune responses and the number of parasites at the site of challenge in mice injected S.C. during the protocol described above. Three groups of eight BALB/c and C57BL/6 mice received S.C. either IPS42 or nonrecombinant BCG or did not receive any vaccine. The mice were then challenged with L. major and killed 120 d
later. The footpad of each mouse was ground in 2 ml RPMI medium and 20 pl tissue homogenate was analysed.
The presence of one or more parasite per ten 40 x magnification fields was scored as positive. In BALB/c mice immunized subcutaneously with IPS42, parasites were detected in two of eight mice. Five of eight mice immunized with BCG and all eight non-immunized mice were infected. In C57BL/6 mice no parasites were detected in any group studied.
The proliferative responses of lymph node cells were also investigated in the different groups of mice listed above. The cells were stimulated in vitro with soluble leishmanial antigen (SLA), as described in Methods. Cells from six of eight mice immunized with IPS42 proliferated vigorously in response to SLA (Fig. 3) . In this group the unresponsive mice were those that had persistent cutaneous lesions. Two of six BALB/c mice immunized with BCG developed a lymphoproliferative response to SLA. The responsive mice had no parasites at the end of the study. All six BALB/c mice of the control group had low proliferative responses. In C57BL/6 mice strong proliferation responses specific to SLA were found in all the groups tested.
IP: 54.70.40.11
On: Sun, 16 Dec 2018 18:00:58
DISCUSSION
Upon clinical recovery from most forms of leishmaniasis, there is often effective and long-lasting resistance to recurrent disease. Several studies have shown that cellmediated immunity, rather than humoral antibodies, plays a role in the host defence and resistance to reinfection. For the cutaneous form of leishmaniasis, T h l subsets of CD4' cells producing y-IFN are principally hostprotective, whereas the Th2 subsets secreting IL-3, IL-4 and IL-5 are disease-promoting (reviewed by Titus e t al., 1772).
Several protective antigens have been reported for murine experimental leishmaniasis. One of these antigens, Gp63, is of particular interest since it is expressed in both promastigote and amastigote stages. This antigen is present in all leishmania1 species tested (Bordier, 1787) and is highly conserved (Webb e t al., 1771) . It has been postulated to play a role in the parasite's entry into the macrophage (Russell & Wilhelm, 1786) and its subsequent survival in the phagolysosome through its non-specific proteinase activity (Chaudhuri et al., 1787 major, although lesion development within this group was less than in untreated and BCG control groups (Connell e t al., 1773) .
In the present study, BALB/c mice were protected against L. major infection by a recombinant BCG expressing Gp63 as a fusion protein with p-lactamase. The same antigen expressed as a fusion protein with the IS900 ORF2 gene product failed to induce protective immunity. This might be due to the level of expression ofgp63, as differences in the expression level of heterologous protein between the two systems have been observed in vitro (a factor of 6 in pblaF*-versus PAN-driven expression) (Timm e t al., 1974b) .
The ability of thegp63-recombinant BCG strain to reduce lesion development after L. major infection seems to be independent of the route of vaccination: only slight differences in the protective responses were observed between the i.v. or S.C. inoculation routes.
The reduction of lesion size in BALB/c mice immunized with recombinant BCG IPS42 correlated with the absence of parasites at the site of challenge. C57BL/6 mice are resistant to leishmaniasis and develop protective proliferative responses during infection. There is no proliferative response during acute disease in BALB/c mice. We found that a cellular response was induced in BALB/c mice immunized with gp63-recombinant BCG. 
